You are viewing the site in preview mode

Skip to main content

Table 2 Selected PICOT questions

From: Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force

QuestionInfluence of adherence to ICS therapy on asthma outcomesInfluence of device type for ICS therapy on asthma outcomesInfluence of smoking on asthma outcomes in patients receiving ICS therapyInfluence of ICS particle size on asthma outcomes
PopulationAsthmatics of all ages prescribed regular maintenance ICSAsthmatics of all ages prescribed regular maintenance ICSAsthmatics of all ages prescribed regular maintenance ICSAsthmatics of all ages prescribed regular maintenance ICS
InterventionAdherence to recommended therapyDifferent inhaler devices/delivery systemsSmokersExtra-fine particles ICS
ComparisonDifferent levels of adherence (e.g. 0–25%, 25–50%, 50–75%, over 75%)Different inhaler systems (pMDI, breath-activated MDI, DPI) for delivering the same moleculeEx/non-smokersFine particles ICS
OutcomesExacerbations, admissions, symptoms, QOLExacerbations, admissions, symptoms, QOLExacerbations, admissions, symptoms, QOLExacerbations, admissions, symptoms, QOL
Time frame≥ 12 months≥ 12 months≥ 12 months≥ 12 months
Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us